학술논문

Four-Repeat Tauopathies: Current Management and Future Treatments
Document Type
article
Source
Neurotherapeutics. 17(4)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Rare Diseases
Dementia
Frontotemporal Dementia (FTD)
Neurodegenerative
Neurosciences
Aging
Clinical Research
Mental Health
Alzheimer's Disease
Clinical Trials and Supportive Activities
Brain Disorders
Acquired Cognitive Impairment
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurological
Clinical Trials as Topic
Disease Management
Forecasting
Humans
Motor Disorders
Tauopathies
Treatment Outcome
4R-tauopathy
progressive supranuclear palsy
Richardson's syndrome
corticobasal syndrome
corticobasal degeneration
atypical parkinsonism
Richardson’s syndrome
Pharmacology and Pharmaceutical Sciences
Public Health and Health Services
Neurology & Neurosurgery
Pharmacology and pharmaceutical sciences
Biological psychology
Language
Abstract
Four-repeat tauopathies are a neurodegenerative disease characterized by brain parenchymal accumulation of a specific isoform of the protein tau, which gives rise to a wide breadth of clinical syndromes encompassing diverse symptomatology, with the most common syndromes being progressive supranuclear palsy-Richardson's and corticobasal syndrome. Despite the lack of effective disease-modifying therapies, targeted treatment of symptoms can improve quality of life for patients with 4-repeat tauopathies. However, managing these symptoms can be a daunting task, even for those familiar with the diseases, as they span motor, sensory, cognitive, affective, autonomic, and behavioral domains. This review describes current approaches to symptomatic management of common clinical symptoms in 4-repeat tauopathies with a focus on practical patient management, including pharmacologic and nonpharmacologic strategies, and concludes with a discussion of the history and future of disease-modifying therapeutics and clinical trials in this population.